A 2007 double-blind, multicenter trial (n=102) showed ALC 1,500 mg/day significantly improved tender point count, total myalgic score, depression, and musculoskeletal pain compared to placebo.[9] A 2015 RCT found ALC 1,500 mg/day comparable to duloxetine 60 mg/day for pain and depression.[8] Most notably, a 2023 RCT demonstrated that adding PEA 1,200 mg/day + ALC 2,000 mg/day to ongoing duloxetine + pregabalin therapy produced significantly greater improvements in Widespread Pain Index, FIQR, and FASmod scores.[7] Role in Treatment: ALC can be used as monotherapy or adjunctive therapy in fibromyalgia
Community cycles describe how the four-peptide KLOW blend is discussed in research protocols
Tng nhy cm Insulin cc bnh nhn i tho ng khng ph thuc Insulin v h tr iu tr vim ty cp, bo v cc c quan kh tc nhn tn cng nh cc cht trung gian ha hc ca cc phn ng vim
In phase 3 trials, maximal dose retatrutide demonstrated 29% placebo-adjusted weight loss at 68 weeks (albeit with higher discontinuation rates than semaglutide and tirzepatide)
It's also important to consider that more is not necessarily better when it comes to supplements for GLP-1-related constipation
